Swansea trial to test earlier radiotherapy for inoperable stomach cancer
A Swansea-led clinical trial will test whether giving radiotherapy earlier and at a higher dose can help people with inoperable stomach cancer. The planned GastroSCOPE study will compare standard treatment with and without additional higher-dose radiotherapy. The recruitment target is 558 patients across 28 centres. Those are planned numbers, rather than a count of people already enrolled or treated. The study has not established that the proposed approach improves outcomes.
What the researchers want to find out
The central questions are whether the additional radiotherapy can slow cancer progression, delay or prevent symptoms and improve quality of life. Random allocation to comparison groups is intended to help researchers establish whether any difference is due to the treatment. Health and Care Research Wales says the trial will include people able to receive chemotherapy and people unable to do so. Standard treatment is therefore not the same for every participant. The announcement should not be read as a recommendation for an individual patient.
Outline of the planned comparison described by Swansea Bay University Health Board and Health and Care Research Wales. This is a study plan, not a result. Original graphic: Cover Wales.
Chart: Cover WalesSource dataCC BY 4.0
Swansea clinicians lead the study
Consultant clinical oncologists Dr Sarah Gwynne and Dr Amy Case are the co-chief investigators. Dr Gwynne works at the South West Wales Cancer Centre at Singleton Hospital. Swansea Bay University Health Board says Cancer Research UK has awarded £3 million for the trial. Health and Care Research Wales reported the funding award in September, so this is an explanation of the planned research rather than a newly announced grant. Alongside the clinical comparison, the team plans to examine imaging techniques, tumour biology and blood markers to investigate why responses to treatment can differ.
A research question, not a new treatment offer
The health board’s account stresses that the evidence is not yet certain enough to change routine treatment. Preparatory work remains before the first sites open and patients are recruited. Neither announcement provides an open recruitment offer or a confirmed starting date for patients. No survival gain, reduction in symptoms or improvement in quality of life can be claimed from this trial before its results are available.
Background and supporting figures
Where this sits
The planned comparison is intended to test benefit; it is not evidence that benefit has already been demonstrated.
558 people across 28 centres is the intended recruitment scale, rather than an achieved enrolment total.